News
- Egalet to Report First Quarter 2017 Financial Results During Investor Day on May 10, 2017 in New YorkSource: Investor NewsPublished on 2017-04-26
- Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement for OXAYDO® (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg Dosage StrengthsSource: Investor NewsPublished on 2017-04-18
- Egalet Corporation Announces Changes to Board of DirectorsSource: Investor NewsPublished on 2017-04-10
- Egalet to Participate in Spring Investor ConferencesSource: Investor NewsPublished on 2017-04-03




